Comparison of molecular (BluePrint+MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial. This is an ASCO Meeting Abstract ...
Influence of primary systemic therapy on minimal residual disease in primary breast cancer. Background: In a new database harbouringthe patients of several prospective phase II neoadjuvant trials (fec ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results